5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine

ID: ALA258694

Chembl Id: CHEMBL258694

PubChem CID: 44449577

Max Phase: Preclinical

Molecular Formula: C19H18N8O

Molecular Weight: 374.41

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  Cc1nnc(-c2cn3ncnc(Nc4cnc5[nH]ccc5c4)c3c2C(C)C)o1

Standard InChI:  InChI=1S/C19H18N8O/c1-10(2)15-14(19-26-25-11(3)28-19)8-27-16(15)18(22-9-23-27)24-13-6-12-4-5-20-17(12)21-7-13/h4-10H,1-3H3,(H,20,21)(H,22,23,24)

Standard InChI Key:  LQNDDQQRHZEHDD-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA258694

   6-(5-methyl-1,3,4-oxadiazol-2-yl)-5-propan-2-yl-N-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 374.41

Molecular Weight (Monoisotopic): 374.1604

AlogP: 3.83

#Rotatable Bonds: 4

Polar Surface Area: 109.82

Molecular Species: NEUTRAL

HBA: 8

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 9

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 3.52

CX LogP: 2.45

CX LogD: 2.45

Aromatic Rings: 5

Heavy Atoms: 28

QED Weighted: 0.49

Np Likeness Score: -1.29

References

1. Ruel R, Thibeault C, L'Heureux A, Martel A, Cai ZW, Wei D, Qian L, Barrish JC, Mathur A, D'Arienzo C, Hunt JT, Kamath A, Marathe P, Zhang Y, Derbin G, Wautlet B, Mortillo S, Jeyaseelan R, Henley B, Tejwani R, Bhide RS, Trainor GL, Fargnoli J, Lombardo LJ..  (2008)  Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor.,  18  (9): [PMID:18395443] [10.1016/j.bmcl.2008.03.057]

Source

Source(1):

• Scientific Literature